Status:
COMPLETED
Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers
Lead Sponsor:
Mansoura University
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Intravesical BCG is the mainstay adjuvant management of high risk NMIBC. Adequacy of immune system stimulation is the determinant factor for patient response to BCG. Immunological markers for BCG-resp...
Detailed Description
Background: Intravesical BCG is the mainstay adjuvant management of high risk NMIBC. Adequacy of immune system stimulation is the determinant factor for patient response to BCG. Immunological markers ...
Eligibility Criteria
Inclusion
- patients with primary or recurrent NMIBC for whom primary TURBT was done.
Exclusion
- Patients with previous BCG instillation,
- benign pathology
- Variant histology
- Non urothelial carcinoma,
- concommitent upper tract urothelial tumors, detrusor muscle invasion
- low or intermediate risk NMIBC
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT04723121
Start Date
March 1 2013
End Date
December 1 2020
Last Update
January 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology and Nephrology Center
Al Mansurah, DK, Egypt, 35516